Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.52 |
| ▸ | AURKA | O14965 | 4/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049480 | 0.92 | AURKA (0.46) | PDE5AAURKAPTPN5SCN2AJAK2 | |
| SCHEMBL4059875 | 0.85 | PDE5A (0.62) | PDE5AAURKAPDE2APDGFRBPDGFRA | |
| SCHEMBL4055971 | 0.85 | AURKA (0.56) | PDE5AAURKAPDE2APDGFRBPDGFRA | |
| SCHEMBL13607927 | 0.83 | GRIN1 (0.49) | PDE5AGRIN1GRIN2BPTPN5SCN2A | |
| SCHEMBL4058461 | 0.83 | SCN2A (0.56) | AURKAGRIN1GRIN2BSCN2A | |
| SCHEMBL4059872 | 0.83 | AURKA (0.61) | AURKAGRIN1GRIN2B | |
| SCHEMBL4050873 | 0.83 | AURKA (0.58) | AURKAGRIN1GRIN2BSCN2APDGFRB | |
| SCHEMBL4057030 | 0.81 | SCN2A (0.53) | AURKASCN2A | |
| SCHEMBL4051168 | 0.80 | PDE5A (0.58) | PDE5AAURKAPDE2APDGFRBPDGFRA | |
| SCHEMBL4060342 | 0.79 | PDE5A (0.57) | PDE5AAURKAPDE2APDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | PDE5A 2762/4885AURKA 247/4885GRIN1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.